differ
type
vaccin
infecti
bovin
rhinotrach
ibr
commerci
avail
among
inactiv
glycoprotein
e
ge
delet
marker
vaccin
commonli
use
abil
induc
passiv
immun
poorli
known
evalu
passiv
immun
transfer
dam
immunis
commerci
inactiv
gedelet
marker
vaccin
calv
vaccin
pregnant
cattl
devoid
neutralis
antibodi
bovin
alphaherpesviru
divid
two
group
anim
group
inject
differ
inactiv
gedelet
marker
vaccin
administr
via
intranas
intramuscular
rout
addit
pregnant
cattl
serv
unvaccin
control
group
calv
number
anim
group
increas
newborn
calv
dam
humor
immun
respons
evalu
calv
subsequ
differ
time
postcalv
day
addit
antibodi
colostrum
milk
serum
sampl
newborn
calv
evalu
differ
time
result
indic
inactiv
glycoprotein
e
ge
delet
marker
vaccin
safe
produc
good
humor
immun
respons
pregnant
cattl
calv
moreov
result
show
calf
serum
passiv
immun
persist
bovin
alphaherpesviru
caus
variou
clinic
syndrom
among
cattl
popul
includ
respiratori
diseas
vagin
balanoposth
abort
enter
enceph
may
observ
acut
infect
subsequ
viral
recrudesc
follow
period
stress
date
finland
sweden
norway
denmark
austria
switzerland
well
provinc
bolzano
itali
success
employ
testandslaught
strategi
european
union
state
implement
compulsori
erad
programm
combin
testandremov
vaccin
use
marker
vaccin
convers
vaccin
strategi
use
usa
nonmark
vaccin
use
marker
vaccin
deriv
delet
one
gene
respons
synthesi
glycoprotein
enzym
europ
glycoprotein
e
ge
gene
marker
commonli
delet
modifi
live
inactiv
diva
differenti
infect
vaccin
anim
vaccin
type
immunis
make
possibl
differenti
anim
immunis
marker
vaccin
ge
neg
infect
inocul
tradit
nondelet
vaccin
ge
posit
diagnost
test
specif
ge
howev
disadvantag
use
live
marker
vaccin
viru
remain
latent
state
immunis
anim
reactiv
excret
follow
exposur
immunosuppress
stimulu
marker
vaccin
administ
intramuscularli
intranas
induc
mark
humor
cellmedi
immun
respons
howev
littl
inform
avail
regard
induct
passiv
immun
regard
tradit
vaccin
sever
report
shown
cattl
vaccin
nondelet
modifiedl
vaccin
transfer
neutralis
antibodi
na
newborn
calv
protect
experiment
infect
studi
demonstr
poor
titr
colostr
antibodi
increas
risk
contract
infect
calf
also
report
concentr
matern
antibodi
calv
birth
colostrum
ingest
directli
proport
present
mother
serum
though
extens
studi
report
marker
vaccin
need
assess
abil
induc
passiv
immun
made
concert
effort
evalu
passiv
immun
transmit
cattl
newborn
calv
follow
immunis
differ
inactiv
marker
vaccin
two
commerci
vaccin
select
studi
tabl
product
identifi
follow
vaccin
geneg
inactiv
strain
contain
light
paraffin
oil
vaccin
b
geneg
inactiv
strain
contain
aluminium
hydroxid
saponin
thiomers
vaccin
administ
follow
dose
ml
given
anim
pregnant
femal
day
apart
vaccin
inject
anim
intranas
wherea
vaccin
b
inject
intramuscularli
im
neck
muscl
cattl
receiv
first
dose
vaccin
inject
month
pregnanc
anim
studi
singl
dairi
herd
locat
central
itali
own
run
local
veterinarian
accord
farm
record
vaccin
use
recent
histori
respiratori
diseas
regist
eighteen
pregnant
friesian
cattl
approxim
year
age
devoid
na
elisa
antibodi
glycoprotein
e
geelisa
select
anim
previous
two
pregnanc
statu
anim
confirm
throughout
experiment
period
base
absenc
clinic
symptom
serolog
virolog
investig
ibr
anim
fed
twice
per
day
unife
mixtur
water
ad
libitum
moreov
calv
milk
perform
three
time
per
day
mainten
experiment
protocol
establish
accord
european
legisl
protect
anim
use
scientif
purpos
experi
carri
approv
italian
ministri
health
authoris
number
number
anim
group
determin
sampl
procedur
envisag
experiment
clinic
studi
use
compar
proport
term
superior
percentag
consid
proport
appear
studi
event
control
group
percentag
use
proport
appear
studi
event
experiment
group
alpha
error
studi
power
cattl
divid
three
group
six
pregnant
anim
first
second
group
inject
vaccin
b
respect
tabl
wherea
third
group
serv
unvaccin
control
group
anim
group
hous
separ
pen
farm
calv
number
anim
cattl
group
increas
six
newborn
calv
fed
l
colostrum
milk
administ
twice
per
day
throughout
experiment
period
subsequ
day
postbirth
newborn
calv
fed
concentr
feed
hay
addit
milk
approxim
day
birth
data
follow
possibl
advers
reaction
vaccin
obtain
local
veterinarian
localis
swell
inject
site
ii
slight
transient
slight
increas
bodi
temperatur
iii
anaphylact
shock
iv
abort
v
stillbirth
vi
birth
weak
unthrifti
calv
case
abort
foetu
placenta
serum
sampl
submit
laboratori
investig
clinic
condit
monitor
throughout
experi
day
vaccin
time
day
day
postvaccin
day
pvd
serum
sampl
collect
cattl
test
presenc
geelisa
antibodi
na
addit
serum
sampl
taken
anim
postcalv
day
pcd
assess
antibodi
gbelisa
geelisa
viru
neutralis
test
vnt
simultan
colostrum
milk
sampl
collect
lactat
cattl
test
gbelisa
geelisa
indirect
elisa
blood
sampl
approxim
ml
collect
coccyg
jugular
vein
pregnant
cattl
calv
respect
anim
dispos
needl
vacutain
tube
use
subsequ
sampl
centrifug
g
min
c
extract
serum
addit
colostrum
milk
sampl
uniformli
collect
teat
anim
obtain
ml
use
conic
tube
later
centrifug
g
min
c
obtain
skim
sampl
sampl
transport
refriger
laboratori
within
h
collect
test
afterward
sampl
store
c
serolog
studi
two
commerci
elisa
test
idexx
ibr
ge
ab
test
main
usa
idexx
ibr
gb
ab
main
usa
use
parallel
examin
collect
sera
colostrum
milk
sampl
addit
indirect
elisa
idexx
bulk
milk
ab
main
usa
use
colostrum
milk
sampl
protocol
describ
kit
manufactur
follow
result
also
express
accord
instruct
manufactur
micropl
read
use
autom
plate
reader
data
analys
use
magellan
softwar
tecan
ag
switzerland
serum
sampl
test
use
protocol
describ
oie
manual
diagnost
test
vaccin
terrestri
anim
briefli
undilut
serum
sampl
twofold
dilut
mix
tcid
lo
angel
strain
microtitr
plate
sampl
incub
c
h
madindarbi
bovin
kidney
cell
ad
well
cell
provid
biobank
veterinari
resourc
bvr
brescia
itali
identifi
code
bs
cl
day
incub
c
plate
read
use
invert
tissu
cultur
microscop
determin
cytopath
effect
neutralis
titr
express
highest
dilut
inhibit
cytopatholog
overal
anim
use
studi
includ
pregnant
cattl
newborn
calv
titr
antibodi
measur
logarithm
scale
base
mean
titr
calcul
anim
group
sampl
time
nonparametr
wilcoxon
mannwhitney
test
use
evalu
presenc
statist
signific
differ
immun
induc
vaccin
two
gedelet
marker
vaccin
unvaccin
control
differ
group
group
b
respect
control
group
sampl
time
studi
consid
signific
level
pvalu
statist
analys
perform
use
stata
softwar
statacorp
lcc
texa
usa
immunis
clinic
sign
advers
reaction
observ
pregnant
cattl
anim
immunis
vaccin
im
vaccin
b
moreov
throughout
experiment
period
clinic
sign
ibr
infect
seen
calv
born
cattl
immunis
vaccin
b
except
two
calv
two
anim
born
vaccin
aimmunis
cattl
show
monolater
discharg
two
month
age
follow
nasal
swab
virolog
bacteriolog
investig
found
infect
one
staphylococcu
spp
consequ
treat
antibiot
ceftiofur
hydrochlorid
day
postvaccin
pregnant
cattl
na
mean
na
titr
log
titr
cattl
vaccin
vaccin
vaccin
b
show
signific
differ
compar
control
p
mean
titr
log
valu
increas
log
p
vaccin
log
p
vaccin
b
seroconvers
detect
unvaccin
control
tabl
day
postcalv
mean
na
titr
cattl
immunis
vaccin
decreas
compar
day
calv
log
p
howev
onward
na
titr
start
declin
continu
till
antibodi
titr
reach
log
p
remain
constant
tabl
convers
day
postcalv
mean
na
titr
cattl
immunis
vaccin
b
decreas
log
p
remain
constant
subsequ
decreas
antibodi
titr
log
p
addit
vaccin
pregnant
cattl
remain
seroposit
gb
seroneg
ge
convers
seroconvers
detect
unvaccin
control
tabl
day
calv
approxim
h
birth
calv
born
vaccin
aimmunis
cattl
na
mean
titr
log
p
remain
constant
titr
decreas
log
p
subsequ
declin
reach
log
p
convers
day
calv
calv
cattl
immunis
vaccin
b
na
titr
log
p
persist
till
start
declin
antibodi
titr
reach
log
p
calv
calv
remain
seroposit
gb
seroneg
ge
contrast
seroconvers
detect
control
group
tabl
colostrum
milk
sampl
collect
cattl
immunis
vaccin
b
seroneg
ge
seroposit
gb
indirect
elisa
antibodi
throughout
experiment
period
contrast
colostrum
milk
sampl
collect
unvaccin
cattl
seroneg
gb
ge
indirect
elisa
antibodi
tabl
current
european
countri
diva
strategi
consid
one
firstlin
intervent
erad
program
area
high
preval
diseas
itali
nation
surveil
plan
ibr
activ
autochthon
cattl
breed
recommend
use
marker
vaccin
decreas
ibr
seropreval
wide
known
marker
vaccin
induc
mark
humor
cellmedi
immun
respons
howev
littl
inform
avail
regard
passiv
immun
induc
vaccin
previou
studi
suggest
passiv
immun
would
induc
calv
matern
vaccin
howev
studi
import
provid
perform
sever
experi
use
two
gedelet
marker
vaccin
administ
via
intranas
vaccin
intramuscular
vaccin
b
rout
inactiv
gedelet
marker
vaccin
induc
clinic
sign
advers
reaction
effect
especi
abort
anaphylact
shock
report
modifiedl
attenu
vaccin
administ
pregnant
cattl
prepartum
period
result
studi
accord
report
previous
suggest
risk
advers
reaction
follow
administr
either
inactiv
gedelet
marker
vaccin
addit
outcom
present
studi
accord
studi
show
vaccin
pregnant
cattl
prevent
ibrinduc
abort
current
known
herpesvirus
involv
cattl
abort
littl
inform
avail
abil
vaccin
prepar
protect
abort
induc
bovin
gammaherpesviru
bovin
alphaherpesviru
respons
vaccin
determin
assess
na
titr
geelisa
serum
pregnant
cattl
result
indic
na
titr
increas
compar
control
level
significantli
p
p
elev
titr
also
observ
find
agreement
studi
increas
colostr
antibodi
product
variou
pathogen
detect
vaccin
pregnant
cattl
prepartum
period
contrast
studi
conduct
lemair
et
al
low
level
antibodi
observ
two
cow
two
vaccin
inactiv
gedelet
marker
vaccin
moreov
calv
declin
matern
antibodi
bovin
viral
diarrhea
viru
shown
day
age
respect
similar
result
also
seen
anoth
studi
vaccin
contain
rotaviru
coronaviru
escherichia
coli
use
immunis
pregnant
cattl
led
high
titr
specif
antibodi
colostrum
milk
agianniotaki
et
al
demonstr
presenc
na
lumpi
skin
diseas
viru
day
postcalv
present
studi
pregnant
cattl
show
neg
result
geelisa
vaccin
period
result
agreement
report
demonstr
serum
sampl
collect
anim
immunis
gedelet
marker
vaccin
also
neg
geelisa
moreov
result
show
experiment
period
field
viru
circul
experiment
group
cattl
natur
experiment
expos
posit
geelisa
antibodi
experi
perform
herein
show
pregnant
cattl
immunis
two
gedelet
marker
vaccin
could
transfer
passiv
immun
calv
fact
day
calv
group
inject
vaccin
b
show
high
na
serum
level
birth
calv
born
agammaglobulinemia
state
need
colostrum
high
level
immunoglobulin
ig
first
h
ig
penetr
bloodstream
bind
fc
receptor
locat
intestin
brush
border
produc
b
cell
plasma
cell
blood
lactat
cow
ig
respons
earli
protect
newborn
differ
infect
furthermor
colostrum
contain
leukocyt
sever
antimicrobi
protein
complement
lactoferrin
lactoperoxidas
lysozym
leukocyt
togeth
matern
ig
involv
confer
orogastr
protect
specif
enter
circul
intestin
adsorpt
promot
neonat
cellular
immun
research
day
calv
cattl
immunis
vaccin
show
good
level
na
decreas
progress
addit
calv
group
show
na
titr
similar
mother
approxim
h
birth
subsequ
antibodi
titr
decreas
end
experi
reach
neg
valu
vaccin
group
differ
antibodi
titr
cattl
newborn
calv
could
due
passag
ig
mother
newborn
colostrum
result
similar
obtain
cervenak
et
al
show
time
calv
approach
igg
massiv
decreas
matern
serum
sampl
bind
mammari
epitheli
cell
igg
releas
colostrum
milk
lactat
calv
undergo
socal
gut
closur
approxim
h
birth
adsorb
colostr
igg
igg
igg
level
fall
antibodi
titr
milk
gradual
decreas
data
obtain
studi
support
result
mechor
et
al
report
correl
serum
na
titr
cattl
newborn
calv
addit
antibodi
titr
observ
group
newborn
calv
born
cattl
immunis
vaccin
b
log
log
respect
lower
requir
protect
infect
sever
studi
shown
na
higher
valu
log
protect
calv
experiment
infect
moreov
shown
antibodi
appear
nasal
secret
calv
earli
first
day
ingest
colostrum
na
secret
respiratori
tract
mucosa
primarili
igg
class
persist
day
birth
serum
antibodi
detect
calv
reach
sever
month
age
result
similar
studi
show
persist
na
use
nonmark
vaccin
studi
carri
base
current
field
condit
differ
variabl
includ
geograph
posit
farm
weather
nutrit
health
statu
herd
gener
dairi
cattl
subject
stress
neg
affect
serolog
respons
vaccin
studi
evid
stressor
intramuscularlyand
intranasallyvaccin
anim
produc
humor
immun
high
antibodi
titr
convers
author
use
modifiedl
vaccin
found
aforement
factor
neg
affect
antibodi
respons
vaccin
studi
challeng
virul
viru
given
research
aim
evalu
abil
two
gedelet
marker
vaccin
induc
passiv
immun
moreov
studi
intend
form
basi
addit
research
evalu
effect
differ
vaccin
ibr
thu
futur
studi
conduct
assess
whether
passiv
immun
calv
protect
experiment
infect
use
virul
viru
overal
two
inactiv
gedelet
marker
vaccin
shown
innocu
pregnant
cattl
ii
effect
transfer
passiv
immun
dam
calv
iii
suitabl
immunis
ibr
erad
program
studi
conduct
evalu
passiv
immun
induc
vaccin
protect
calv
challeng
virul
wt
strain
author
contribut
conceptu
sp
cr
ci
stata
softwar
es
methodolog
investig
er
cp
pg
gv
data
curat
cr
cp
manuscript
write
review
edit
sp
gmdm
author
read
agre
publish
version
manuscript
